Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Xi‐Tai Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2884-6748; OpenAlex author ID A5101679360. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: 4 papers · 2025: none · 2026: 3 papers

Papers 11

  1. Synergistic Induction of Ferroptosis by GPX4 Inhibitor and GSH-Depleted Nanoparticles Effectively Reverses Gemcitabine Resistance in Pancreatic Ductal Adenocar… Co-author DOI 10.1002/adhm.202503694↗
  2. Positive Feedback Loop of Histone Lactylation-Driven HNRNPC Promotes Autophagy to Confer Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance. Co-author DOI 10.1002/advs.202510483↗
  3. The 30% reduction of baseline CA19-9 could stratify the prognosis of advanced pancreatic ductal adenocarcinoma with RECIST stable disease after first-line chem… First author DOI 10.1186/s12885-026-16353-z↗
  4. Epigenetic Activation of the CMTM6-IGF2BP1-EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202406714↗
  5. Platelet-Derived Growth Factor C Facilitates Malignant Behavior of Pancreatic Ductal Adenocarcinoma by Regulating SREBP1 Mediated Lipid Metabolism. Co-author DOI 10.1002/advs.202407069↗
  6. CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy. Co-author DOI 10.1016/j.canlet.2024.216640↗
  7. N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance. Co-author DOI 10.1038/s41388-024-03092-3↗
  8. HNRNPC impedes m6A-dependent anti-metastatic alternative splicing events in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.07.016↗
  9. Targeting Super-Enhancers via Nanoparticle-Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.201902926↗
  10. Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.1039/d0nr03138k↗
  11. The C/EBPβ-LINC01133 axis promotes cell proliferation in pancreatic ductal adenocarcinoma through upregulation of CCNG1. Co-author DOI 10.1016/j.canlet.2018.02.020↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiao-Yu Yin · 8 shared papers, 2018–2026 · strength 1.56
  2. Jie‐Qin Wang · 7 shared papers, 2020–2026 · strength 1.24
  3. Chen‐Song Huang · 7 shared papers, 2018–2026 · strength 1.22
  4. Ying‐Qin Zhu · 5 shared papers, 2024–2026 · strength 1.04
  5. Mingjian Ma · 5 shared papers, 2024–2026 · strength 1.04
  6. Yin-Hao Shi · 4 shared papers, 2024 · strength 0.75
  7. Zhide Liu · 4 shared papers, 2024 · strength 0.75
  8. Xiaoyu Yin · 3 shared papers, 2020–2026 · strength 0.52
  9. Wei Zhao · 4 shared papers, 2018–2024 · strength 0.51
  10. Xin Zhang · 1 shared paper, 2026 · strength 0.32
  11. Xiao‐Xu Zhu · 2 shared papers, 2018–2021 · strength 0.23
  12. Yue Huang · 1 shared paper, 2024 · strength 0.18
  13. Liying Wang · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.